
3d3 min read
Medical Article
Background Crohn’s disease (CD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract characterized by transmural inflammation leading to strictures, fistulae, and progressive bowel damage (1). Despite significant advances with biologic agents such as anti-TNF, anti-integrin, and IL-12/23 inhibitors, many patients experience s

Mirikizumab in Moderate-to-Severe Crohn’s Disease: A Phase 3 Randomized Controlled Trial Synopsis
Similar Content

Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments

Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments

Treatment of Recurrent Adult Medulloblastoma
2602 Reached1 Comments4 Likes

Total Hip Arthroplasty in a Patient with Congenital Insensitivity to Pain
358 Reached4 Comments5 Likes

Chronic Cough in Adolescent
282 Reached1 Comments6 Likes